Drug Patents owned by Genzyme Corp

1. List of Caprelsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42353 GENZYME CORP Quinazoline derivatives and pharmaceutical compositions containing them
Jun, 2022

(7 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642608 GENZYME CORP Quinazoline derivatives as VEGF inhibitors
Feb, 2022

(a year ago)

US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474
Aug, 2028

(5 years from now)

Drugs and Companies using VANDETANIB ingredient

Market Authorisation Date: 06 April, 2011

Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Cerdelga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916802 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(9 months ago)

US7196205 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Jun, 2026

(3 years from now)

US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615573 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Apr, 2022

(9 months ago)

US7253185 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(9 months ago)

US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(7 years from now)

US10888544 GENZYME CORP Methods for treating Gaucher disease
Dec, 2038

(15 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with mild hepatic impairment and are concurrently taking a strong or moderate cyp3a inhibitor

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in